VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
This Quarter Return
+10.35%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$113M
AUM Growth
+$113M
(-1.9%)
Cap. Flow
-$8.35M
Cap. Flow
% of AUM
-7.38%
Top 10 Holdings %
Top 10 Hldgs %
14.17%
Holding
280
New
34
Increased
62
Reduced
100
Closed
19
Top Buys
| 1 |
Fidelity MSCI Financials Index ETF
FNCL
|
$1.41M |
| 2 |
iShares 20+ Year Treasury Bond ETF
TLT
|
$1.15M |
| 3 |
Verastem
VSTM
|
$985K |
| 4 |
Arrowhead Research
ARWR
|
$933K |
| 5 |
Cartesian Therapeutics
RNAC
|
$884K |
Top Sells
Sector Composition
| 1 | Healthcare | 77.9% |
| 2 | Financials | 0.8% |
| 3 | Technology | 0.58% |
| 4 | Consumer Discretionary | 0.4% |
| 5 | Energy | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
RDUS
101
DELISTED
Radius Health, Inc.
RDUS
| $700K | 0.62% | 23,749 -7,264 | -23% | -$214K |
|
102
Inovio Pharmaceuticals
INO
$126M
| $699K | 0.62% | 178,365 +3,583 | +2% | +$14K |
|
|
EPZM
103
DELISTED
Epizyme, Inc
EPZM
| $694K | 0.61% | 51,203 -8,127 | -14% | -$110K |
|
104
Biogen
BIIB
$19.4B
| $693K | 0.61% | 2,388 -438 | -15% | -$127K |
|
|
BPMC
105
DELISTED
Blueprint Medicines
BPMC
| $688K | 0.61% | 10,840 +811 | +8% | +$51.5K |
|
106
Theravance Biopharma
TBPH
$699M
| $682K | 0.6% | 30,055 -2,934 | -9% | -$66.6K |
|
107
Denali Therapeutics
DNLI
$2.23B
| $680K | 0.6% | +44,617 | New | +$680K |
|
108
Lexicon Pharmaceuticals
LXRX
$400M
| $680K | 0.6% | 56,636 -33,209 | -37% | -$399K |
|
109
Insmed
INSM
$28.8B
| $679K | 0.6% | 28,718 +4,309 | +18% | +$102K |
|
110
Ultragenyx Pharmaceutical
RARE
$2.89B
| $676K | 0.6% | 8,794 -8,189 | -48% | -$629K |
|
|
ITCI
111
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $675K | 0.6% | 38,174 -11,914 | -24% | -$211K |
|
112
Adicet Bio
ACET
$59.9M
| $673K | 0.6% | +73,570 | New | +$673K |
|
113
Omeros
OMER
$283M
| $673K | 0.6% | 37,076 -10,200 | -22% | -$185K |
|
114
Corbus Pharmaceuticals
CRBP
$115M
| $671K | 0.59% | 132,890 +30,397 | +30% | +$153K |
|
115
Incyte
INCY
$16.5B
| $671K | 0.59% | 10,024 +487 | +5% | +$32.6K |
|
116
Novavax
NVAX
$1.21B
| $671K | 0.59% | 500,964 -63,580 | -11% | -$85.2K |
|
|
ACOR
117
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $665K | 0.59% | 23,175 -20,478 | -47% | -$588K |
|
|
PTLA
118
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $664K | 0.59% | 17,590 -1,613 | -8% | -$60.9K |
|
119
Viking Therapeutics
VKTX
$3.04B
| $658K | 0.58% | +69,305 | New | +$658K |
|
|
AGEN
120
Agenus
AGEN
$133M
| $656K | 0.58% | 288,833 +76,290 | +36% | +$173K |
|
|
MNTA
121
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $649K | 0.57% | 31,740 -36,744 | -54% | -$751K |
|
122
Halozyme
HALO
$8.56B
| $648K | 0.57% | 38,423 -7,397 | -16% | -$125K |
|
|
BLUE
123
DELISTED
bluebird bio
BLUE
| $647K | 0.57% | 4,120 -32 | -0.8% | -$5.03K |
|
124
Agios Pharmaceuticals
AGIO
$2.19B
| $645K | 0.57% | 7,652 -6,753 | -47% | -$569K |
|
125
Ionis Pharmaceuticals
IONS
$6.8B
| $642K | 0.57% | 15,418 -2,164 | -12% | -$90.1K |
|